COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom. Show more
Location: 33 Broadwick Street, London, W1F 0DQ, United Kingdom | Website: https://compasspathways.com | Industry: Medical Care Facilities | Sector: Healthcare
Market Cap
259.2M
52 Wk Range
$2.25 - $8.54
Previous Close
$2.77
Open
$2.78
Volume
2,866,209
Day Range
$2.68 - $2.90
Enterprise Value
31.09M
Cash
260.1M
Avg Qtr Burn
-36.0M
Insider Ownership
13.64%
Institutional Own.
56.03%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
COMP360 (Psilocybin) Details Treatment Resistant Depression | Phase 3 Data readout | |
COMP360 (Psilocybin) Details Anorexia nervosa | Phase 2 Update | |
COMP360 (Psilocybin) Details Post-traumatic stress disorder | Phase 2 Update |